Microvesicles from cerebrospinal fluid of patients with Alzheimer's disease display reduced concentrations of tau and APP protein

被引:31
|
作者
Spitzer, Philipp [1 ]
Mulzer, Linda-Marie [1 ]
Oberstein, Timo Jan [1 ]
Munoz, Luis Enrique [2 ]
Lewczuk, Piotr [1 ,3 ]
Kornhuber, Johannes [1 ]
Herrmann, Martin [2 ]
Maler, Juan Manuel [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Dept Psychiat & Psychotherapy, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[3] Med Univ Bialystok, Dept Neurodegenerat Diagnost, Bialystok, Poland
关键词
MILD COGNITIVE IMPAIRMENT; CIRCULATING MICROPARTICLES; ASSOCIATION WORKGROUPS; EXTRACELLULAR VESICLES; DIAGNOSTIC GUIDELINES; MEMBRANE-PARTICLES; NATIONAL INSTITUTE; NEURONAL EXOSOMES; AMYLOID-BETA; DEMENTIA;
D O I
10.1038/s41598-019-43607-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Microvesicles are small membranous particles generated during cellular activation or stress. The analysis of the content and the surface of microvesicles allow conclusions about the cells they are originating from and the underlying pathology. Therefore, CSF microvesicles have been suggested to be promising targets to monitor the (etio) pathology of neurodegenerative diseases. Microvesicles in the CSF of 15 patients with Alzheimer's disease and 15 controls were analyzed by flow cytometry regarding the levels of CD3, CD4, CD45, CD64, BACE1, A beta, APP and tau. The results were replicated in a second cohort comprising 14 patients with Alzheimer's disease and 9 controls. The levels of tau and APP were reduced in microvesicles of Alzheimer's disease patients. A significant change was neither observed in the number of microvesicles nor in the expression of the other antigens. Tau and APP in microvesicles separated patients with Alzheimer's disease from controls with an AUC of 0.84 and 0.89 respectively. We conclude that tau and APP in CSF microvesicles are promising biomarkers which could directly provide information about the Alzheimer pathology on a cellular level.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
    Mattsson, Niklas
    Insel, Philip S.
    Palmqvist, Sebastian
    Portelius, Erik
    Zetterberg, Henrik
    Weiner, Michael
    Blennow, Kai
    Hansson, Oskar
    EMBO MOLECULAR MEDICINE, 2016, 8 (10) : 1184 - 1196
  • [42] Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease
    Maruyama, M
    Higuchi, M
    Takaki, Y
    Matsuba, Y
    Tanji, H
    Nemoto, M
    Tomita, N
    Matsui, T
    Iwata, N
    Mizukami, H
    Muramatsu, SI
    Ozawa, K
    Saido, TC
    Arai, H
    Sasaki, H
    ANNALS OF NEUROLOGY, 2005, 57 (06) : 832 - 842
  • [43] Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease
    Blennow K.
    NeuroRX, 2004, 1 (2): : 213 - 225
  • [44] tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease?
    Blennow, K
    Wallin, A
    Agren, H
    Spenger, C
    Siegfried, J
    Vanmechelen, E
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) : 231 - 245
  • [45] Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
    Mecocci, P
    Cherubini, A
    Bregnocchi, M
    Chionne, F
    Cecchetti, R
    Lowenthal, DT
    Senin, U
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (03): : 211 - 214
  • [46] Reduced Levels of Amyloid-β-Binding Proteins in Cerebrospinal Fluid from Alzheimer's Disease Patients
    Hansson, Sara F.
    Andreasson, Ulf
    Wall, Mariann
    Skoog, Ingmar
    Andreasen, Niels
    Wallin, Anders
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (02) : 389 - 397
  • [47] Concentrations of Matrix Metalloproteinases and their Tissue Inhibitors in the Cerebrospinal Fluid of Patients with Alzheimer's Disease
    Mroczko, Barbara
    Groblewska, Magdalena
    Zboch, Marzena
    Kulczynska, Agnieszka
    Koper, Olga M.
    Szmitkowski, Maciej
    Kornhuber, Johannes
    Lewczuk, Piotr
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 40 (02) : 351 - 357
  • [48] Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease
    Bekris, L. M.
    Galloway, N. M.
    Millard, S.
    Lockhart, D.
    Li, G.
    Galasko, D. R.
    Farlow, M. R.
    Clark, C. M.
    Quinn, J. F.
    Kaye, J. A.
    Schellenberg, G. D.
    Leverenz, J. B.
    Seubert, P.
    Tsuang, D. W.
    Peskind, E. R.
    Yu, C. E.
    NEUROBIOLOGY OF AGING, 2011, 32 (03) : 556.e13 - 556.e23
  • [49] Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease
    Johansson, Per
    Almqvist, Erik G.
    Bjerke, Maria
    Wallin, Anders
    Johansson, Jan-Ove
    Andreasson, Ulf
    Blennow, Kaj
    Zetterberg, Henrik
    Svensson, Johan
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 59 (03) : 1017 - 1026
  • [50] Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
    Arai, H
    Higuchi, S
    Sasaki, H
    GERONTOLOGY, 1997, 43 : 2 - 10